详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

7| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [2]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China. [3]Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

出处：

DOI：

ISSN：

摘要：

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton's tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL.ClinicalTrials.gov number, NCT04666168.Copyright © 2022 Zhang, Huang, Liu, Zhang, Li, Yin, Wang, Liu and Liu.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2022]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 7.3 出版当年[2022版] 8 出版当年五年平均 8.787 出版前一年[2021版] 5.7 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：